pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·May 1·1 min read
save

Save the date: Premium subscriber-exclusive Post-Hoc Live

Q1 earnings recap with Endpoints News After a deal-heavy first quarter, earnings season is in full swing. We're breaking down the news and trends from Big Pharma's first-quarter calls on a special premium subscriber-exclusive episode ...

May 1, 2026·read at Endpoints ↗

May 1, 2026 11:23 AM EDT DealsR&D Save the date: Pre­mi­um sub­scriber-ex­clu­sive Post-Hoc Live ENDPOINTS Q1 earn­ings re­cap with End­points News Af­ter a deal-heavy first quar­ter, earn­ings sea­son is in full swing. We’re break­ing down the news and trends from … This article is available only to Premium subscribers Upgrade to Premium for unlimited access and Premium exclusives. UPGRADE LOG IN

source

Reporting by Endpoints.

read at Endpoints ↗
61 words · retrieved May 1
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
Big Pharma

related stories

  • Jul 21Novartis stays 'geography-agnostic' in dealmaking amid flurry of China dealsBioSpace
  • Jul 21‘We’ve been looking for a novel approach’: Why Novartis CEO ended ADC holdout for $1.5B Myricx dealFierce Biotech
  • Jul 20Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelicsBioSpace
  • Jul 20BMS expands AI footprint with Nvidia, aiming for ‘most powerful AI factory in life sciences’Fierce Biotech
  • Jul 18‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelicsFierce Biotech